Liu Xiaochun, Li Tingting, Zhang Jia, Lin Xiling, Wang Wenzhen, Fan Xiaodong, Wang Lili
Third Hospital of Shanxi Medical University, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Taiyuan, China.
Key Laboratory of Cellular Physiology at Shanxi Medical University, Ministry of Education, and the Department of Physiology, Shanxi Medical University, Taiyuan, China.
Front Cell Dev Biol. 2023 Jan 13;11:1007703. doi: 10.3389/fcell.2023.1007703. eCollection 2023.
Stress urinary incontinence (SUI) adversely affects the quality of life of patients, while the currently available surgical and non-surgical therapies are not effective in all patients. Application of mesenchymal stem cells (MSCs) for regaining the ability to control urination has attracted interest. Herein, we reviewed the literature and analyzed recent studies on MSC-based therapies for SUI, summarized recent treatment strategies and their underlying mechanisms of action, while assessing their safety, effectiveness, and prospects. In addition, we traced and sorted the root literature and, from an experimental design perspective, divided the obtained results into four categories namely single MSC type therapy for SUI, MSC-based combination therapy for SUI, treatment of SUI with the MSC secretome, and other factors influencing MSC therapy. Although evidence demonstrates that the treatment strategies are safe and effective, the underlying mechanisms of action remain nebulous, hence more clinical trials are warranted. Therefore, future studies should focus on designing clinical trials of MSC-based therapies to determine the indications for treatment, cell dosage, appropriate surgical strategies, and optimal cell sources, and develop clinically relevant animal models to elucidate the molecular mechanisms underlying stem cell therapies improvement of SUI.
压力性尿失禁（SUI）对患者的生活质量产生不利影响，而目前可用的手术和非手术治疗方法并非对所有患者都有效。应用间充质干细胞（MSCs）恢复排尿控制能力已引起关注。在此，我们回顾了文献并分析了最近关于基于MSCs治疗SUI的研究，总结了近期的治疗策略及其潜在作用机制，同时评估了它们的安全性、有效性和前景。此外，我们追溯并整理了原始文献，并从实验设计的角度将获得的结果分为四类，即用于SUI的单一MSC类型治疗、基于MSCs的SUI联合治疗、用MSC分泌组治疗SUI以及影响MSC治疗的其他因素。尽管有证据表明这些治疗策略是安全有效的，但其潜在作用机制仍不明确，因此需要更多的临床试验。因此，未来的研究应侧重于设计基于MSCs治疗的临床试验，以确定治疗适应症、细胞剂量、合适的手术策略和最佳细胞来源，并开发与临床相关的动物模型，以阐明干细胞治疗改善SUI的分子机制。
